Beovu

RSS

brolucizumab

Authorised
This medicine is authorised for use in the European Union.

Overview

Beovu is a medicine used to treat adults with certain sight problems caused by damage to the retina (the light-sensing layer at the back of the eye), and more specifically its central region, known as the macula. The macula provides central vision that is needed to see detail for everyday tasks such as driving, reading and recognising faces. In adults, Beovu is used to treat:

• the ‘wet’ form of age-related macular degeneration (AMD). The wet form of AMD is caused by choroidal neovascularisation (the abnormal growth of blood vessels under the macula, which may lead to leakage of fluid and blood and cause swelling);

• visual impairment due to macular oedema (swelling of the macula) caused by diabetes (DME).

Beovu contains the active substance brolucizumab.

This EPAR was last updated on 25/01/2023

Authorisation details

Product details
Name
Beovu
Agency product number
EMEA/H/C/004913
Active substance
brolucizumab
International non-proprietary name (INN) or common name
brolucizumab
Therapeutic area (MeSH)
Wet Macular Degeneration
Anatomical therapeutic chemical (ATC) code
S01
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
Novartis Europharm Limited 
Revision
6
Date of issue of marketing authorisation valid throughout the European Union
13/02/2020
Contact address

Vista Building
Elm Park
Merrion Road
Dublin 4
D04 A9N6 
Ireland

Product information

15/12/2022 Beovu - EMEA/H/C/004913 - II/0019

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Ophthalmologicals

Therapeutic indication

Beovu is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (AMD).

Assessment history

Related content

How useful was this page?

Add your rating
Average
3 ratings
2 ratings
1 rating